Journal of Clinical Immunology

, Volume 32, Issue 3, pp 595–603 | Cite as

Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine

  • Jacob Atsmon
  • Efrat Kate-Ilovitz
  • Dimitry Shaikevich
  • Yossi Singer
  • Inna Volokhov
  • Kirsten Y. Haim
  • Tamar Ben-Yedidia



A new vaccine, Multimeric-001, containing conserved linear epitopes from the HA, NP, and M1 proteins of influenza type A and type B strains was designed to protect against seasonal and pandemic influenza virus strains, regardless of mutations. We assessed its safety and tolerability and characterized humoral and cellular immune responses elicited by its administration.


Sixty healthy volunteers received either 250 or 500 μg injections, with or without adjuvant (Montanide ISA 51VG), or matching placebo. Two intramuscular injections were administered, 21 days apart.


Treatment was well tolerated and no significant adverse events were noted. Forty-two days after first injection, there was a 50-fold and 37-fold increase in IgG titers against Multimeric-001 protein, following the adjuvanted 500 and 250 μg doses, respectively. Sera from immunized subjects lysed MDCK cells infected with strains of influenza representing the major strains that infect humans: H1N1, H3N2, and influenza B. Proliferation of peripheral blood mononuclear cells as well as increase in IL-2 and IFN-gamma secretion occurred following incubation with the vaccine.


This vaccine model differs fundamentally from the current influenza virus vaccines, as it does not contain the variable regions of the virus hemagglutinin and hence does not induce hemagglutination inhibition antibodies that serve as surrogate markers for protection. In order to demonstrate the potential efficacy of the Multimeric-001, an alternative assay was employed, in which the lysis of MDCK cells infected with different virus strains was shown, with the involvement of the complement mechanism. The humoral and cellular responses suggest a cross-immunity of the vaccine toward influenza virus strains regardless of mutations. These results corroborate the protective effect of the vaccine, previously shown in animals. Larger-scale studies are under way to further substantiate the safety and efficacy of the vaccine candidate.


Multimeric-001 influenza universal vaccine epitope 


  1. 1.
    World Health Organization. Recommended composition of influenza virus vaccines for use in the 2011 southern hemisphere influenza season. Accessed 9 Apr 2011.
  2. 2.
    Centers for Disease Control and Prevention. Seasonal Influenza (Flu). Accessed 9 Apr 2011.
  3. 3.
    Prevention and Control of Influenza; Recommendations of the Advisory Committee on Immunization Practices (ACIP). Accessed 9 Apr 2011.
  4. 4.
    Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24(8):1159–69.PubMedCrossRefGoogle Scholar
  5. 5.
    Hans D, Young P, Fairlie D. Current status of short synthetic peptides as vaccines. Med Chem. 2006;2(6):627–46.PubMedGoogle Scholar
  6. 6.
    Rötzschke O, Falk K, Stevanović S, Jung G, Walden P, Rammensee H. Exact prediction of a natural T cell epitope. Eur J Immunol. 1991;21(11):2891–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Ben-Yedidia T, Arnon R. Design of peptide and polypeptide vaccines. Curr Opin Biotechnol. 1997;8(4):442–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Snyder J, Belyakov I, Dzutsev A, Lemmonier F, Berzofsky J. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol. 2004;78:7052–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Hsu S, Chargelegue D, Obeid O, Steward M. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. J Gen Virol. 1999;80(Pt 6):1401–5.PubMedGoogle Scholar
  10. 10.
    Azizi A, Diaz-Mitoma F. Viral peptide immunogens: current challenges and opportunities. J Pept Sci. 2007;13(12):776–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Kashala O, Amador R, Valero M, et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine. 2002;20(17–18):2263–77.PubMedCrossRefGoogle Scholar
  12. 12.
    Nardin E, Oliveira G, Calvo-Calle J, et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis. 2000;182(5):1486–96.PubMedCrossRefGoogle Scholar
  13. 13.
    Engler O, Dai W, Sette A, Hunziker I, Reichen J, Pichler W, Cerny A. Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol Immunol. 2001;38(6):457–65.PubMedCrossRefGoogle Scholar
  14. 14.
    Gahery H, Daniel N, Charmeteau B, Ourth L, Jackson A, Andrieu M, Choppin J, Salmon D, Pialoux G, Guillet J. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res Hum Retroviruses. 2006;22(7):684–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Pinto L, Berzofsky J, Fowke K, et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS. 1999;13(15):2003–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Levi R, Arnon R. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine. 1996;14(1):85–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Ben-Yedidia T, Abel L, Arnon R, Globerson A. Efficacy of anti-influenza peptide vaccine in aged mice. Mech Ageing Dev. 1998;104:11–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Ben-Yedidia T, Marcus H, Reisner Y, Arnon R. Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Int Immunol. 1999;11:1043–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Hsu JC. Multiple comparisons theory and methods. London: Chapman & Hall; 1996.Google Scholar
  20. 20.
    Quinnan G, Ennis F, Tuazon C, et al. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun. 1980;30(2):362–9.PubMedGoogle Scholar
  21. 21.
    Saurwein-Teissl M, Zisterer K, Schmitt T, Glück R, Cryz S, Grubeck-Loebenstein B. Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. Clin Exp Immunol. 1998;114(2):271–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, Venditti M, Capone I, Seif I, De Maeyer E, Tough D, Donatelli I, Belardelli F. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol. 2002;169(1):375–83.PubMedGoogle Scholar
  23. 23.
    Peek L, Middaugh C, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 2008;60(8):915–28.PubMedCrossRefGoogle Scholar
  24. 24.
    Valmori D, Souleimanian N, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A. 2007;104(21):8947–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jacob Atsmon
    • 1
  • Efrat Kate-Ilovitz
    • 2
  • Dimitry Shaikevich
    • 1
  • Yossi Singer
    • 2
  • Inna Volokhov
    • 1
  • Kirsten Y. Haim
    • 1
  • Tamar Ben-Yedidia
    • 2
  1. 1.Clinical Research CenterTel Aviv Sourasky Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv UniversityTel AvivIsrael
  2. 2.BiondVax Pharmaceuticals Ltd.Ness ZionaIsrael

Personalised recommendations